Preliminary analysis of a phase II study of Heptazyme™, a nuclease resistant ribozyme targeting hepatitis C virus (HCV) RNA.

被引：0
|
作者：
Tong, M
Schiff, E
Jensen, DM
Jacobsen, I
Eversen, G
McHutchison, JG
Aitchison, R
Gordon, GS
Babcock, SA
Enright, JH
Maloney, L
Sandberg, JA
Blatt, L
机构：
[1] Huntington Mem Hosp, Pasadena, CA USA
[2] Univ Miami, Sch Med, Miami, FL 33152 USA
[3] Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA
[4] New York Presbyterian Hosp, New York, NY USA
[5] Univ Colorado, Hlth Sci Ctr, Denver, CO 80202 USA
[6] Scripps Clin, La Jolla, CA USA
[7] Ribozyme Pharmaceut Inc, Boulder, CO USA
来源：
HEPATOLOGY | 2002年 / 36卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
788
引用
收藏
页码：360A / 360A
页数：1
相关论文
共 50 条
  • [1] Safety analysis of a phase I study of HEPTAZYME™, a nuclease resistant ribozyme targeting hepatitis C (HCV) RNA.
    Sandberg, JA
    Rossi, SJ
    Gordon, GS
    Turik, MA
    Braun, DK
    Aitchison, R
    Babcock, SA
    Hansen, B
    Wright, T
    Blatt, LM
    HEPATOLOGY, 2001, 34 (04) : 333A - 333A
  • [2] Synthesis and testing of nuclease resistant hammerhead ribozymes directed against hepatitis C virus RNA.
    Roberts, EC
    Malmstrom, TA
    Pavco, PA
    Domenico, KK
    Bellon, L
    Conrad, AJ
    Tong, MJ
    Blatt, LM
    HEPATOLOGY, 1998, 28 (04) : 398A - 398A
  • [3] Inhibition of viral replication by nuclease resistant hammerhead ribozymes directed against hepatitis C virus RNA.
    Macejak, DJ
    Jensen, KL
    Bellon, L
    Pavco, PA
    Blatt, LM
    HEPATOLOGY, 1999, 30 (04) : 409A - 409A
  • [4] A novel ribozyme-based method for the direct detection of Hepatitis C virus RNA.
    Seiwert, S
    Vaish, N
    Andrews, L
    Zinnen, S
    Beigelman, L
    Blatt, L
    HEPATOLOGY, 2001, 34 (04) : 219A - 219A
  • [5] VERSANT™ HCV RNA Qualitative Assay:: Sensitive and specific detection of hepatitis C virus RNA.
    Spidle, JA
    Roma, G
    Pham, J
    Sanders, M
    Bott, M
    Pollner, R
    HEPATOLOGY, 2001, 34 (04) : 228A - 228A
  • [6] Lack of effect of ribavirin on serum levels of hepatitis C virus (HCV) and hepatitis G virus (HGV) RNA.
    Marrone, A
    Shih, JWK
    Nakatsuji, Y
    Alter, HJ
    Lau, D
    Herion, D
    Vergalla, J
    Hoofnagle, JH
    HEPATOLOGY, 1996, 24 (04) : 394 - 394
  • [7] Second generation ribozyme development: Improved hepatic delivery of a nuclease-resistant ribozyme targeting the hepatitis B virus RNA using galactosamine conjugation.
    Jackson, TE
    Kong, LH
    Turnbow, C
    Hartsough, KC
    France, M
    Serebryany, V
    Adamic, J
    Radka, S
    Dickinson, B
    Zinnen, S
    Vargeese, C
    Shaffer, C
    Simon, S
    Bowman, K
    Lewis, A
    Blatt, L
    Beigleman, L
    Lee, P
    Morrissey, D
    HEPATOLOGY, 2002, 36 (04) : 645A - 645A
  • [8] Nuclease-resistant ribozymes targeting the minus strand of hepatitis C virus (HCV) RNA can inhibit the replication of a chimeric virus in cell culture.
    Macejak, DG
    Jensen, KL
    Mokler, V
    Pavco, PA
    Blatt, LM
    HEPATOLOGY, 2001, 34 (04) : 449A - 449A
  • [9] Hepatitis C virus (HCV) in the serum of anti-HCV-positive individuals: Detection of HCV core protein and HCV RNA.
    Raker, CA
    Tabor, E
    Okayama, A
    Yu, MYW
    Kohara, M
    Mueller, NE
    Tsubouchi, H
    Stuver, SO
    HEPATOLOGY, 2002, 36 (04) : 568A - 568A
  • [10] A 9 month chronic toxicology study of HEPTAZYME™ [a ribozyme directed against hepatitis C virus (HCV) RNA] administered as a daily subcutaneous injection in non-human primates.
    Lee, PA
    Blanchard, KS
    Blatt, LM
    HEPATOLOGY, 2001, 34 (04) : 601A - 601A
12345